Facebook Linkedin RSS Twitter Youtube
Home 2022

Regeneron

Regeneron to Acquire Checkmate for $250M, Expanding Cancer I/O Pipeline
Drug Discovery

Regeneron to Acquire Checkmate for $250M, Expanding Cancer I/O Pipeline

Therapeutic Advances Using In Vivo CRISPR Genome Editing
Genome Editing

Therapeutic Advances Using In Vivo CRISPR Genome Editing

FDA Expands Regeneron EUA for COVID-19 Antibody “Cocktail”
Coronavirus

FDA Expands Regeneron EUA for COVID-19 Antibody “Cocktail”

U.S. OKs EUA for Genentech’s Actemra vs. COVID-19; Halts Distribution of Lilly’s Antibody Combo
Coronavirus

U.S. OKs EUA for Genentech’s Actemra vs. COVID-19; Halts Distribution of Lilly’s Antibody Combo

“New Era of Medicine”: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans
Genome Editing

“New Era of Medicine”: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans

Eli Lilly, Regeneron Report Positive Phase III COVID-19 Antibody Results
Coronavirus

Eli Lilly, Regeneron Report Positive Phase III COVID-19 Antibody Results

Gene Therapy Pioneer, Regeneron Partner on Nasal Spray vs. COVID-19
Coronavirus

Gene Therapy Pioneer, Regeneron Partner on Nasal Spray vs. COVID-19

Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
Coronavirus

Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19

Regeneron “Cocktail” Reduces Viral Load; Dosing Change Weighed
Coronavirus

Regeneron “Cocktail” Reduces Viral Load; Dosing Change Weighed

Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained
Coronavirus

Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained

123...11Page 2 of 11
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.